Abeona Therapeutics (ABEO) Total Non-Current Liabilities (2010 - 2026)

Abeona Therapeutics' Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $40.0 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 20.6% year-over-year to $40.0 million; the TTM figure through Mar 2026 stood at $40.0 million (up 20.6% YoY), while the FY2025 annual figure was $41.5 million, up 26.05% from the prior year.
• Total Non-Current Liabilities was $40.0 million for Q1 2026 at Abeona Therapeutics, down from $41.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $73.7 million in Q3 2024 to a low of $16.9 million in Q3 2023.
• Historically, Total Non-Current Liabilities has averaged $31.9 million across 5 years, with a median of $32.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities jumped 335.51% in 2024, then tumbled 49.41% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $17.8 million in 2022, then increased by 0.16% to $17.8 million in 2023, then jumped by 84.5% to $32.9 million in 2024, then increased by 26.05% to $41.5 million in 2025, then slipped by 3.41% to $40.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $40.0 million (Q1 2026), $41.5 million (Q4 2025), and $37.3 million (Q3 2025), per Business Quant data.